The US has begun late stage clinical trials into a drug formulated to fight Covid-19, according to AFP.
The Phase 3 trial will initially enroll some 300 volunteers around the world who have been hospitalised with mild to moderate Covid-19 with fewer than 13 days of symptoms.
“Studying the impact of this investigational therapeutic on multiple patient populations at the same time is critical to determining whether it can help Covid-19 patients with differing levels of disease severity,” said Anthony Fauci, director of the National Institutes of Allergies and Infectious Diseases.
